©The Author(s) 2026.
World J Transplant. Mar 18, 2026; 16(1): 114367
Published online Mar 18, 2026. doi: 10.5500/wjt.v16.i1.114367
Published online Mar 18, 2026. doi: 10.5500/wjt.v16.i1.114367
Figure 4 Preferred induction therapy by immunologic risk category.
A and B: Induction therapy preferred by specialists for recipients with high (A) and low (B) immunological risk. ATLG: Anti-human-T-lymphocyte immunoglobulin; IL-2RB: Interleukin-2 receptor anatagonists; ATG: Anti-thymocyte globulin.
- Citation: Kute VB, Balwani MR, Shrimali JB, Pasari A, Kher V, Patel MP, Chafekar D, Guditi S, Das P, Siddaiah GM, Godara SM, Bhargava V, Gupta A, Ramteke V, Deshpande N, Tolani P, Prasad N, Patil RK, Mohanka R, Mahajan S, Sharma S, Banerjee S, Engineer DP, Agarwal D, Kashiv P, Lahiri A, Khullar D, Srivastava A. Induction therapy in kidney transplant recipients: A consensus statement of Indian Society of Organ Transplantation. World J Transplant 2026; 16(1): 114367
- URL: https://www.wjgnet.com/2220-3230/full/v16/i1/114367.htm
- DOI: https://dx.doi.org/10.5500/wjt.v16.i1.114367